Cargando…
Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy
INTRODUCTION: Galactose-deficient IgA1 (Gd-IgA1) is a critical pathogenic factor for IgA nephropathy (IgAN), but its value as a disease-specific biomarker remains controversial. We aimed to clarify the clinical significance of Gd-IgA1 in patients with IgAN. METHODS: We retrospectively reviewed 111 p...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214568/ https://www.ncbi.nlm.nih.gov/pubmed/30388165 http://dx.doi.org/10.1371/journal.pone.0206865 |
_version_ | 1783367995297366016 |
---|---|
author | Wada, Yukihiro Matsumoto, Kei Suzuki, Taihei Saito, Tomohiro Kanazawa, Nobuhiro Tachibana, Shohei Iseri, Ken Sugiyama, Motonori Iyoda, Masayuki Shibata, Takanori |
author_facet | Wada, Yukihiro Matsumoto, Kei Suzuki, Taihei Saito, Tomohiro Kanazawa, Nobuhiro Tachibana, Shohei Iseri, Ken Sugiyama, Motonori Iyoda, Masayuki Shibata, Takanori |
author_sort | Wada, Yukihiro |
collection | PubMed |
description | INTRODUCTION: Galactose-deficient IgA1 (Gd-IgA1) is a critical pathogenic factor for IgA nephropathy (IgAN), but its value as a disease-specific biomarker remains controversial. We aimed to clarify the clinical significance of Gd-IgA1 in patients with IgAN. METHODS: We retrospectively reviewed 111 patients who were diagnosed with IgAN based on the findings of renal biopsies (RB) at Showa University Hospital since 2007. Serum Gd-IgA1 (s-Gd-IgA1) at the time of RB was compared among 111 IgAN patients, 18 Henoch-Schönlein purpura nephritis (HSPN) patients, 29 lupus nephritis (LN) patients, 28 ANCA-associated vasculitis (AAV) patients, and 13 minimal change disease (MCD) patients using ELISA with an anti-human Gd-IgA1-specific monoclonal antibody (KM55). We also immunohistochemically stained paraffin-embedded sections for mesangial Gd-IgA1 (m-Gd-IgA1) deposition using KM55. RESULTS: Although levels of s-Gd-IgA1 were comparable among IgAN and HSPN, s-Gd-IgA1 levels were significantly elevated in patients with IgAN compared with LN, AAV and MCD (IgAN vs. HSPN, LN, AAV, and MCD: 16.2 ± 9.1 vs. 14.2 ± 10.8, p = 0.263; 12.7 ± 9.4, p = 0.008; 13.1 ± 7.3, p = 0.059; and 8.2 ± 4.8 μg/mL, p<0.001, respectively). Mesangial-Gd-IgA1 deposition was specifically detected in IgAN or HSPN. The increase in s-Gd-IgA1 significantly correlated with m-Gd-IgA1 positivity in patients with IgAN, and s-Gd-IgA1 elevation and m-Gd-IgA1 deposition were evident in patients with histopathologically advanced IgAN. Moreover, s-Gd-IgA1 levels were significantly higher in IgAN patients with glomerular sclerosis and tubulo-interstitial lesions. Mesangial-Gd-IgA1 intensity negatively correlated with eGFR in IgAN. Multivariate analysis selected s-Gd-IgA1 elevation as a significant risk factor for a 30%-reduction in eGFR in IgAN (HR, 1.37; 95% CI, 1.02–1.89; p = 0.038). CONCLUSIONS: Although IgAN and HSPN remain difficult to differentiate, s-Gd-IgA1 elevation and m-Gd-IgA1 deposition are reliable diagnostic factors that reflect IgAN severity. Serum-Gd-IgA1 could serve as a predictor of renal outcomes in IgAN. Thus, Gd-IgA1 could be significant biomarker for patients with IgAN. |
format | Online Article Text |
id | pubmed-6214568 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-62145682018-11-19 Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy Wada, Yukihiro Matsumoto, Kei Suzuki, Taihei Saito, Tomohiro Kanazawa, Nobuhiro Tachibana, Shohei Iseri, Ken Sugiyama, Motonori Iyoda, Masayuki Shibata, Takanori PLoS One Research Article INTRODUCTION: Galactose-deficient IgA1 (Gd-IgA1) is a critical pathogenic factor for IgA nephropathy (IgAN), but its value as a disease-specific biomarker remains controversial. We aimed to clarify the clinical significance of Gd-IgA1 in patients with IgAN. METHODS: We retrospectively reviewed 111 patients who were diagnosed with IgAN based on the findings of renal biopsies (RB) at Showa University Hospital since 2007. Serum Gd-IgA1 (s-Gd-IgA1) at the time of RB was compared among 111 IgAN patients, 18 Henoch-Schönlein purpura nephritis (HSPN) patients, 29 lupus nephritis (LN) patients, 28 ANCA-associated vasculitis (AAV) patients, and 13 minimal change disease (MCD) patients using ELISA with an anti-human Gd-IgA1-specific monoclonal antibody (KM55). We also immunohistochemically stained paraffin-embedded sections for mesangial Gd-IgA1 (m-Gd-IgA1) deposition using KM55. RESULTS: Although levels of s-Gd-IgA1 were comparable among IgAN and HSPN, s-Gd-IgA1 levels were significantly elevated in patients with IgAN compared with LN, AAV and MCD (IgAN vs. HSPN, LN, AAV, and MCD: 16.2 ± 9.1 vs. 14.2 ± 10.8, p = 0.263; 12.7 ± 9.4, p = 0.008; 13.1 ± 7.3, p = 0.059; and 8.2 ± 4.8 μg/mL, p<0.001, respectively). Mesangial-Gd-IgA1 deposition was specifically detected in IgAN or HSPN. The increase in s-Gd-IgA1 significantly correlated with m-Gd-IgA1 positivity in patients with IgAN, and s-Gd-IgA1 elevation and m-Gd-IgA1 deposition were evident in patients with histopathologically advanced IgAN. Moreover, s-Gd-IgA1 levels were significantly higher in IgAN patients with glomerular sclerosis and tubulo-interstitial lesions. Mesangial-Gd-IgA1 intensity negatively correlated with eGFR in IgAN. Multivariate analysis selected s-Gd-IgA1 elevation as a significant risk factor for a 30%-reduction in eGFR in IgAN (HR, 1.37; 95% CI, 1.02–1.89; p = 0.038). CONCLUSIONS: Although IgAN and HSPN remain difficult to differentiate, s-Gd-IgA1 elevation and m-Gd-IgA1 deposition are reliable diagnostic factors that reflect IgAN severity. Serum-Gd-IgA1 could serve as a predictor of renal outcomes in IgAN. Thus, Gd-IgA1 could be significant biomarker for patients with IgAN. Public Library of Science 2018-11-02 /pmc/articles/PMC6214568/ /pubmed/30388165 http://dx.doi.org/10.1371/journal.pone.0206865 Text en © 2018 Wada et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Wada, Yukihiro Matsumoto, Kei Suzuki, Taihei Saito, Tomohiro Kanazawa, Nobuhiro Tachibana, Shohei Iseri, Ken Sugiyama, Motonori Iyoda, Masayuki Shibata, Takanori Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy |
title | Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy |
title_full | Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy |
title_fullStr | Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy |
title_full_unstemmed | Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy |
title_short | Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy |
title_sort | clinical significance of serum and mesangial galactose-deficient iga1 in patients with iga nephropathy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214568/ https://www.ncbi.nlm.nih.gov/pubmed/30388165 http://dx.doi.org/10.1371/journal.pone.0206865 |
work_keys_str_mv | AT wadayukihiro clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy AT matsumotokei clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy AT suzukitaihei clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy AT saitotomohiro clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy AT kanazawanobuhiro clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy AT tachibanashohei clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy AT iseriken clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy AT sugiyamamotonori clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy AT iyodamasayuki clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy AT shibatatakanori clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy |